Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28418221 | 0.81 | GSK3B (0.35) | CYP1A2CYP2D6MAPK1GSK3BADORA2A | |
| SCHEMBL29116493 | 0.75 | GSK3B (0.36) | GSK3BADORA2AADORA1 | |
| Threonine SCHEMBL28960545 | 0.73 | YTHDC1 (0.45) | ADORA2AADORA1ADORA2B | |
| SCHEMBL29089559 | 0.72 | ADORA2A (0.64) | MAPK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL29089554 | 0.72 | ADORA2A (0.64) | MAPK1ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL26981136 | 0.71 | ADORA2A (0.38) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL29835052 | 0.71 | ADORA2A (0.38) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL19462601 | 0.71 | TARS1 (0.55) | ADORA2AADORA1ADORA2B | |
| SCHEMBL2346678 | 0.69 | GSK3B (0.67) | GSK3BADORA2AADORA1ALDH1A1ADORA2B | |
| SCHEMBL3273477 | 0.68 | GSK3B (0.49) | GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751285-A | Lipid compounds and lipid nanoparticle compositions | 中生复诺健生物科技(上海)有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-116829578-B | Polynucleotides encoding interleukin-12 (IL-12) and compositions and methods related thereto | 苏州艾博生物科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119654141-A | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-117083291-B | Coronavirus nucleic acid vaccine based on sequences derived from SARS-CoV-2 Delta strain | 苏州艾博生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119451976-A | Mutant fragments of VZV glycoprotein E | 苏州艾博生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119137160-A | Nucleic acid vaccine for Respiratory Syncytial Virus (RSV) | 苏州艾博生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-117580587-B | Coronavirus nucleic acid vaccine based on sequences derived from SARS-CoV-2 Omikovia strain | 苏州艾博生物科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118715201-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118697900-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118647397-A | Polynucleotide composition and use thereof | 辉瑞公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-117069785-A | Lipid compounds and lipid nanoparticle compositions | 中生复诺健生物科技(上海)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117043343-A | Nucleic acid vaccine for mutant coronaviruses | 苏州艾博生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117003658-A | Lipid Nanoparticle Compositions | 苏州艾博生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116940685-A | Coronavirus multivalent nucleic acid vaccine based on sequences derived from SARS-CoV-2Beta and Delta strains | 苏州艾博生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116829578-A | Polynucleotides encoding interleukin-12 (IL-12) and compositions and methods related thereto | 苏州艾博生物科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116782889-A | Enhanced formulation stability and improved lyophilization process | 生物技术欧洲股份公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116670267-A | Tetravalent mRNA vaccine for influenza virus | 苏州艾博生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116472275-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116323627-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114206827-B | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |